The National Institute for Health and Care Excellence (NICE) has now recommended that Tecentriq (atezolizumab) from Roche may be used within...
The FDA has restricted use of Keytruda (pembrolizumab) from Merck Inc.and Tecentriq (atezolizumab) from Roche among patients with locally advanced...
Genentech/Roche announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) met its co-primary endpoints.
Genentech announced data from the positive, pivotal Phase III OAK study of Tecentriq (atezolizumab) which showed Tecentriq helped people live...
Genentech/Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound);...
The European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab), from Roche, in combination with chemotherapy (carboplatin and...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tecentriq (atezolizumab ) from Genentech/Roche.
Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide...
Genentech, announced positive results from the Phase III IMpassion130 study of Tecentriq (atezolizumab) plus chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for...
Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval...